Small cell lung carcinoma with KIF5B-RET fusion partially responded to the 4th-line therapy with anlotinib: A case report

Figure 2 Imaging evaluations and serum tumor biomarker testing during treatment. A-G: Imaging assessments of the tumor were conducted during the 1st to 4^th line chemotherapy, yellow arrows were used to indicate primary tumors and metastatic lesions; H: Serum levels of progastrin-releasing peptide, neuron-specific enolase, and carbohydrate antigen 125 were measured to monitor clinical responses. NSE: Neuron-specific enolase; CA125: Carbohydrate antigen 125; ProGRP: Progastrin-releasing peptide.